Molecular virology in transfusion medicine laboratory

Blood Transfusion

Volumn 11, Issue 2, 2013, Pages 203-216

  Candotti, Daniel ^a,b   Allain, Jean Pierre ^b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Blood safety; Bloodborne viruses; Genetic variability; Nucleic acid testing; Transfusion

Indexed keywords

FLUDARABINE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEIC ACID; VIRUS DNA; VIRUS RNA;

ACTIVE IMMUNIZATION; BLOOD BANK; BLOOD DONOR; BLOOD TRANSFUSION; CHIKUNGUNYA ALPHAVIRUS; CLINICAL LABORATORY; FRACTIONATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS E VIRUS; HERPES VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PARVOVIRUS B19; LABORATORY DIAGNOSIS; MEDICINE; MOLECULAR EPIDEMIOLOGY; MUTATION RATE; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; REVIEW; SCREENING; THROMBOCYTOPHERESIS; TORQUE TENO VIRUS; TRANSFUSION; ULTRACENTRIFUGATION; VIROLOGY; VIRUS DETECTION; VIRUS GENOME; VIRUS LOAD; WEST NILE FLAVIVIRUS;

BLOOD; BLOOD SAFETY; BLOOD TRANSFUSION; DNA, VIRAL; HUMANS; RNA, VIRAL; VIRUS DISEASES; VIRUSES;

EID: 84876934311     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0219-12     Document Type: Review

References (88)

1. Comanor L, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 2006;91:1-12. (Pubitemid 43822298)
2. Roth WK, Busch MP, Schuller A, et al. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012;102:82-90.
3. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49(Suppl. 2):1S-29S.
4. Busch MP, Tobler LH, Saldanha J, et al. Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003. Transfusion 2005;45:492-9.
5. O'Brien SF, Zou S, Laperche S, et al. Surveillance of transfusion-transmissible infections: comparison of systems in five developed countries. Transfus Med Rev 2012;26:38-57.
6. Busch M, Walderhaug M, Custer B, et al. Risk assessment and cost-effectiveness/utility analysis. Biologicals 2009;37:78-87.
7. Assal A, Barlet V, Deschaseaux M, et al. Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201. Transfusion 2009;49:289-300.
8. Laperche S, Morel P, Deschaseaux M, et al. HIV antibody screening remains indispensable for ensuring viral safety of blood components despite NAT implementation. Transfusion 2003;43:1428-32. (Pubitemid 37322504)
9. Nübling CM, Heiden M, Chudy M, et al. Experience of mandatory nucleic acid testing (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion 2009;49:1850-8.
10. Schmidt M, Korn K, Nübling CM, et al. First transmission of human immunodeficiency virus type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion 2009;49:1836-44.
11. Candotti D, Allain JP. The utility of multiplex NAT in blood screening. Dev Biol (Basel) 2007;127:71-86.
12. Fryer JF, Baylis SA, Gottlieb AL, et al. Development of working reference materials for clinical virology. J Clin Virol 2008;43:367-71.
13. Roth WK, Seifried E. The German experience with NAT. Transfus Med 2002;12:255-8. (Pubitemid 35024255)
14. Jarvis LM, Simmonds P. Scottish experience with NAT. Transfus Med 2002;12:259-64. (Pubitemid 35024256)
15. Owusu-Ofori S, Temple J, Sarkodie F, et al. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resourcepoor settings. Transfusion 2005;45:133-40. (Pubitemid 40180128)
16. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-7.
17. Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005;45:254-64. (Pubitemid 40180144)
18. Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009;49:2454-89.
19. Satake M, Taira R, Yugi H, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007;47:1197-205. (Pubitemid 46934327)
20. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010;50:1495-504.
21. Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol 2009;51:798-809.
22. Tsoi WC, Lelie N, Lin CK. Enhanced HBV detection in Hong Kong blood donors with the second generation triplex transcription mediated amplification assay. Vox sang 2012;103(Suppl. 1):P-296.
23. Vermeulen M, Coleman C, Lelie N, et al. Ehancement of HBV NAT yield rate after introduction of the Ultrio Plus assay. Vox Sang 2012;103(Suppl. 1):P-295.
24. Margaritis AR, Brown SM, Seed CR, et al. Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA. Transfusion 2007;47:1783-93. (Pubitemid 47438540)
25. Candotti D, Temple J, Owusu-Ofori s, Allain JP. Multiplex realtime quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. J Virol Methods 2004;118:39-47. (Pubitemid 38648773)
26. Mine H, Emura H, Miyamoto M, et al. High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan. J Virol Methods 2003;112:145-51. (Pubitemid 37338268)
27. Allain JP, Candotti D. Diagnostic algorithm for HBV safe transfusion. Blood Trans 2009;7:174-82.
28. Li L, Chen PJ, Chen MH, et al. A pilot study for dcreening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus. Transfusion 2008;48:1198-1206. (Pubitemid 351793490)
29. Vermeulen M, Lelie N, Sykes W, et al. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009;49:1115-25.
30. Stramer SL, Krysztof DE, Brodsky JP, et al. Sensitivity comparison of two Food and Drug Administration-licensed, triplex nucleic acid test automated assays for hepatitis B virus DNA detection and associated projections of United States yield. Transfusion 2011;51:2012-22.
31. Candotti D, Lin CK, Belkhiri D, et al. Occult hepatitis B infection in blood donors from South East Asia: molecular characterization and potential mechanisms of occurrence. Gut 2012; gutjnl-2011-301281.
32. Candotti D, Grabarczyk P, Ghiazza P, et al. Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol 2008;49:537-47.
33. Roth WK, Weber M, Seifried E. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet 1999;353:359-63. (Pubitemid 29088163)
34. Zahn A, Allain JP. Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography. J Gen Virol 2005;86:677-85. (Pubitemid 40331248)
35. Satoh K, Iwata-Takakura A, Yoshikawa A, et al. A new method of concentrating hepatitis B virus (HBV) DNA and HBV surface antigen: an application of the method to the detection of occult HBV infection. Vox sang 2008;95:174-80.
36. Berger A, Preiser W. Viral genome quantification as a tool for improving patient management: the example of HIV, HBV, HCV and CMV. J Antimicrob Chemother 2002;49:713-21. (Pubitemid 34546003)
37. Fiebig EW, Wright DJ, Rawaal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003;17:1871-79. (Pubitemid 37070272)
38. Tabuchi A, Tanaka J, Katayama K, et al. Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. J Med Virol 2008;80:2064-8.
39. Yoshikawa A, Gotanda Y, Minegishi K, et al. Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis b surface antigennegative) infection in the acute phase. Transfusion 2007;47:1162-71. (Pubitemid 46934305)
40. Schüttler CG, Caspari G, Jursch CA, et al. Hepatitis C transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet 2000;355:41-2. (Pubitemid 30072185)
41. Busch MP, Tobler LH, Gerlich WH, et al. Very low level viremia in HCV infectious unit missed by NAT. Transfusion 2003;43:1173-4. (Pubitemid 37022381)
42. Ferreira MC, Nel TJ. Differential transmission of human immunodeficiency virus (HIV) via blood components from an HIV-infected donor. Transfusion 2006;46:156-7. (Pubitemid 43381800)
43. Lee TH, Kleinman SH, Wen L, et al. Distribution of parvovirus B19 DNA in blood compartments and persistence of virus in blood donors. Transfusion 2011;51:1896-1908.
44. Kleinman SH, Glynn SA, Lee TH, et al. A linked donorrecipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009;114:3677-83.
45. Matsumoto C, Tadokoro K, Fujimura K, et al. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion 2001;41:878-84. (Pubitemid 32642759)
46. Wang JT, Lee CZ, Chen PJ, et al. Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers. Transfusion 2002;42:1592-7.
47. Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, et al. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol 2008;48:1022-5.
48. El Chaar M, El Jisr T, Allain JP. Hepatitis B virus DNA splicing in lebanese blood donors and genotype a to e strains: implications for hepatitis B virus DNA quantification and infectivity. J Clin Microbiol 2012;50:3159-67.
49. Foglieni B, Candotti D, Guarnori I, et al. A cluster of human immunodeficiency virus type 1 recombinant form escaping detection by commercial genomic amplification assays. Transfusion 2011;51:719-30.
50. Chudy M, Weber-Schehl M, Pichl L, et al. Blood screening nucleic acid amplification tests for human immunodeficiency virus type 1 may require two different amplification targets. Transfusion 2012;52:431-9.
51. Edelmann A, Kalus U, Oltmann A, et al. Improvement of an ultrasensitive human immunodeficiency virus type 1 real-time reverse transcriptase-polymerase chain reaction targeting the long terminal repeat region. Transfusion 2010;50:685-92.
52. Servant A, Laperche S, Lallemand F, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002;76:9124-34. (Pubitemid 34919871)
53. Parsyan A, Szmaragd C, Allain JP, Candotti D. Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes. J Gen Virol 2007;88:428-31. (Pubitemid 46210880)
54. Baylis SA, Shah N, Minor PD. Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma. J Virol Methods 2004;121:7-16. (Pubitemid 39180020)
55. Baylis SA, Fryer JF, Grabarczyk P. Effects of probe binding mutations in an assay designed to detect parvovirus B19: implications for the quantitation of different virus genotypes. J Virol Methods 2007;139:97-9. (Pubitemid 44854221)
56. Koppelman MH, Rood IG, Fryer JF, et al. Parvovirus B19 genotypes 1 and 2 detection with real-time polymerase chain reaction assays. Vox Sang 2007;93:208-15. (Pubitemid 47373990)
57. Cunningham P, Marriott D, Harris C, et al. False negative HIV-1 proviral DNA polymerase chain reaction in a patient with primary infection acquired in Thailand. J Clin Virol 2003;26:163-9. (Pubitemid 36206601)
58. Wirden M, Tubiana R, Marguet F, et al. Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes. J Clin Microbiol 2009;47:1543-5.
59. Koppelman MH, Zaaijer HL. Diversity and origin of hepatitis B virus in Dutch blood donors. J Med Virol 2004;73:29-32. (Pubitemid 38429143)
60. Davidson F, Lycett C, Sablon E, et al. Hepatitis B virus genotypes and precore mutations in Scottish blood donors. Vox Sang 2005;88:87-92. (Pubitemid 40362923)
61. Delwart E, Slikas E, Stramer SL, et al. Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis 2012;205:875-85.
62. Hübschen JM, Mihneva Z, Mentis AF, et al. Phylogenetic analysis of human parvovirus b19 sequences from eleven different countries confirms the predominance of genotype 1 and suggests the spread of genotype 3b. J Clin Microbiol 2009;47:3735-8.
63. Mahgoub S, Candotti D, El Ekiaby M, Allain JP. Hepatitis B virus (HBV) infection and recombination between HBV genotypes D and E in asymptomatic blood donors from Khartoum, Sudan. J Clin Microbiol 2011;49:298-306.
64. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20:W13-23. (Pubitemid 44611051)
65. Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011;364:236-47.
66. Soldan K, Barbara JAJ, Dow BC. Transfusion-transmitted hepatitis B virus infection in the UK: a small and moving target. Vox Sang 2002;83:305-8. (Pubitemid 35434351)
67. Inaba S, Ito A, Miyata Y, et al. Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusion. Transfusion 2006;46:2028-9. (Pubitemid 44631612)
68. Wendel S, Levi JE, Biagini S, et al. Aprobable case of hepatitis B virus transfusion transmission revealed after a 13-monthlong window period. Transfusion 2008;48:1602-8.
69. Hollinger FB, Dodd RY. Hepatitis B virus traceback and lookback: factors to consider. Transfusion 2009;49:176-184.
70. Kretzschmar E, Chudy M, Nübling CM, et al. First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: a comparative study with various assays. Vox Sang 2007;92:297-301. (Pubitemid 46642989)
71. Niederhauser C, Weingand T, Candotti D, et al. Fatal outcome of a hepatitis B virus transfusion-transmitted infection. Vox Sang 2010;98:504-7.
72. Tamura A, Shimizu YK, Tanaka T, et al. Persistent infection of hepatitis E virus transmitted by blood transfusion in a patient with T-cell lymphoma. Hepatol Res 2007;37:113-20. (Pubitemid 46403826)
73. Haïm-Boukobza S, Ferey MP, Vetillard AL, et al. Transfusiontransmitted hepatitis E in a misleading context of autoimmunity and drug-induced toxicity. J Hepatol 2012; DOI: 10.1016/j.jhep. 2012.08.001.
74. Niederhauser C, Candotti D, Weingand T, et al. Reverse vertical transmission of hepatitis B virus (HBV) infection from a transfusion-infected newborn to her mother. J Hepatol 2012;56:734-7.
75. Power JP, El Chaar M, Temple J, et al. HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted hepatitis B virus. J Hepatol 2010;53:780-7.
76. Servant-Delmas A, Laperche S, Mercier M, et al. Limits of sequencing and phylogenetic analysis to assess B19V transmission by single-donor blood component. Vox Sang 2011;100:254-5.
77. Philippe H, Brinkmann H, Lavrov DV, et al. Resolving difficult phylogenetic questions: why more sequences are not enough. PLoS Biology 2011; DOI: 10.1371/journal.pbio.1000602.
78. Vermeulen M, Dickens C, Lelie N, et al. Hepatitis B virus transmission by blood transfusion during 4 years of individualdonation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion 2012;52:880-92.
79. Llewelyn CA, Wells AW, Amin M, et al. The EASTR study: a new approach to determine the reasons for transfusion in epidemiological studies. Transfus Med 2009;19:89-98.
80. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009;113:3147-53.
81. Cannon MJ, Operskalski EA, Mosley JW, et al. J Infect Dis 2009;199:1592-8.
82. Vamvakas EC. Is human herpesvirus-8 transmitted by transfusion? Transfus Med Rev 2010;24:1-14.
83. Gobbini F, Owusu-Ofori S, Marcelin AG, et al. Human herpesvirus 8 transfusion transmission in Ghana, an endemic region of West Africa. Transfusion 2012; DOI: 10.1111/j.1537-2995.2012.03607.x.
84. Qu L, Triulzi DJ, Rowe DT, Jenkins FJ. Detection of HHV-8 (human herpesvirus-8) genomes in induced peripheral blood mononuclear cells (PBMCs) from US blood donors. Vox Sang 2011;100:267-71.
85. Sakata H, Matsubayashi K, Takeda H, et al. A nationwide survey for hepatitis E virus prevalence in Japanese blood donors with elevated alanine aminotransferase. Transfusion 2008;48:2568-76.
86. Bajpai M, Gupta E. Transfusion-transmitted hepatitis E: is screening warranted? Indian J Med Microbiol 2011;29:353-8.
87. Ikeda H, Matsubayashi K, Sakata H, et al. Prevalence of hepatitis E virus infection among Japanese blood donors. ISBT Science Series 2009;4:299-301.
88. Delwart E. Human parvovirus 4 in the blood supply and transmission by pooled plasma-derived clotting factors: does it matter? Transfusion 2012;52:1398-403.